The Lundquist Institute Out-Licenses Development of a Synthetic Lung Surfactant Formulation
Retrieved on:
Monday, March 8, 2021
This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated.
Key Points:
- This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated.
- "Naturally-occurring lung surfactant is a lipid-protein mixture that prevents lung collapse through surface tension reduction," said Frans Walther, MD, the lead Lundquist Investigator.
- "Lack of lung surfactant leads to respiratory distress syndrome in premature infants and can be treated with animal-derived surfactant administration into the windpipe.
- Our research demonstrated that inhalation of a dry powder synthetic lung surfactant formulation with an advanced surfactant protein analog can improve breathing and lung function in surfactant-deficient animals.